Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cognition Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related neurodegenerative diseases such as Alzheimer's disease and Lewy body dementia. Its lead candidate, zervimesine (CT1812), aims to protect neurons by displacing toxic protein oligomers at synapses. The company leverages biomarker-driven clinical trials, strategic collaborations, and proprietary drug libraries to address unmet medical needs in CNS disorders.
This description was generated via AI from an annual report. Updated about 1 year ago.